Zai Lab (NASDAQ:ZLAB) Stock Price Up 13% After Earnings Beat

Key Points

• Zai Lab shares rose 13% after quarterly results beat expectations: its loss was $0.41 per ADS versus the $0.59 forecast, while revenue of $108.21 million slightly exceeded estimates.
• The company remains loss-making, and reports cited declining revenue, tempering the positive earnings surprise. Zai Lab is advancing its drug pipeline, with a potential first U.S. drug filing highlighted as a longer-term catalyst.
• Analysts’ consensus rating is “Moderate Buy”, with an average price target of $37.25.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report)'s share price was up 13% during trading on Friday after the company announced better than expected quarterly earnings. The company traded as high as $25.40 and last traded at $25.5380. 826,219 shares changed hands during trading, a decline of 7% from the average session volume of 884,654 shares. The stock had previously closed at $22.60.

The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.18. The firm had revenue of $108.21 million during the quarter, compared to the consensus estimate of $107.90 million. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%.

Key Zai Lab News

Here are the key news stories impacting Zai Lab this week:

• Positive Sentiment: Zai Lab reported a loss of $0.41 per ADS, beating the consensus estimate of a $0.59 loss. Revenue of $108.21 million also slightly topped the $107.90 million analyst estimate. The earnings beat likely supported investor sentiment. Earnings flash
• Positive Sentiment: The company said it is advancing internally developed medicines, with coverage highlighting the pipeline’s potential to reach a first U.S. drug filing. Progress toward that milestone could offer a longer-term growth catalyst. Zai Lab Q3 2026: Loss Narrows 27%, Pipeline Eyes First US Drug Filing
• Negative Sentiment: Despite the estimate beat, Zai Lab remains loss-making, and reports characterized quarterly revenue as declining. Those trends temper the positive earnings surprise. Zai Lab Q3 Loss Widens, Revenue Declines

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ZLAB shares. Wall Street Zen raised Zai Lab from a "sell" rating to a "hold" rating in a research note on Saturday, September 26th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a research report on Tuesday, October 6th. Citigroup increased their price objective on shares of Zai Lab from $44.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Zai Lab in a report on Tuesday, October 27th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.25.

Insider Buying and Selling

In related news, Director William Lis sold 8,506 shares of the firm's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $25.00, for a total transaction of $212,650.00. Following the transaction, the director owned 41,931 shares of the company's stock, valued at $1,048,275. This trade represents a 16.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 9,385 shares of company stock valued at $235,145. 4.88% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zai Lab

Institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in Zai Lab in the third quarter valued at $62,000. Nykredit A S acquired a new position in shares of Zai Lab in the 2nd quarter worth approximately $79,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Zai Lab in the 3rd quarter valued at about $211,000. WealthPlan Investment Management LLC acquired a new position in Zai Lab during the 3rd quarter valued at approximately $969,000. Finally, Headlands Technologies LLC raised its holdings in shares of Zai Lab by 142.0% during the second quarter. Headlands Technologies LLC now owns 68,010 shares of the company's stock valued at $1,292,000 after buying an additional 39,901 shares during the last quarter. 41.65% of the stock is currently owned by hedge funds and other institutional investors.

Zai Lab Stock Performance

The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of -15.00 and a beta of 0.77. The business's 50 day moving average price is $24.64 and its two-hundred day moving average price is $21.02.

Zai Lab Company Profile

Zai Lab Ltd. NASDAQ: ZLAB is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.